Curran Terrie 4

4 · Arcutis Biotherapeutics, Inc. · Filed Jun 9, 2026

AI-generated summary of this filing

Updated Jun 10, 2026

Arcutis (ARQT) Director Terrie Curran Receives RSU Awards

What Happened

Terrie Curran, a non-employee director of Arcutis Biotherapeutics (ARQT), was granted compensation-related equity on June 5, 2026: 5,778 restricted stock units (RSUs) and 16,667 derivative awards (total 22,445 units). All awards were recorded at $0.00 (no cash paid). These are grants — not open-market purchases or sales.

Key Details

Transaction date: June 5, 2026. Report filed June 9, 2026 (timely under the two-business-day Form 4 rule).
Prices: $0.00 per unit (award/grant).
Total units granted: 5,778 RSUs + 16,667 derivative awards = 22,445 units.
Shares owned after transaction: not specified in the provided filing.
Footnotes:
- F1: The 5,778 RSUs are payable 1-for-1 upon vesting; the Reporting Person elected to defer settlement under an RSU Deferral Election Form (adopted Dec 22, 2025).
- F2: The 16,667 derivative awards’ underlying shares vest/become exercisable 100% on the earlier of the first anniversary of the grant date or immediately before the next annual meeting, subject to continued service.
Filing timeliness: filed June 9, 2026 for a June 5 transaction — appears timely.

Context

These awards are routine director compensation (RSUs/derivative awards) that convert to common stock only upon vesting; no shares were sold or purchased on the open market. Such grants are common for non-employee directors and reflect compensation rather than an immediate trading signal.

Form 4

Period: 2026-06-05

Director

Transactions

Award
Common Stock
[F1]
2026-06-05+5,778→ 23,526 total
Award
Stock Option (right to buy)
[F2]
2026-06-05+16,667→ 16,667 total
Exercise: $21.23Exp: 2036-06-05→ Common Stock (16,667 underlying)

Footnotes (2)

[F1]Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Upon vesting of the RSUs, the settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on December 22, 2025, maintained by the Company.
[F2]The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.

Signature

/s/ Latha Vairavan, as Attorney-in-Fact for Terrie Curran|2026-06-09

1 file